NCT04701060

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

A Prospective, One-arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma With a High Risk of Recurrence

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence

Conditions

• Resectable Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w	preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year

Timeline

• Start date: 2021-01-26
• Primary completion: 2024-03-04
• Completion: 2024-10-04
• First posted: 2021-01-08
• Last updated: 2024-12-03

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study